TITLE

Goserelin not related to increased risk for CV death

AUTHOR(S)
Pollack, Alan
PUB. DATE
March 2008
SOURCE
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p36
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research on the link between goserelin and cardiovascular (CV) presented during the 2008 Genitourinary Cancers Symposium in San Francisco, California from February 14 to 16, 2008. According the study by Dr. Jason Efstathiou and colleagues, higher CV mortality in men with locally advanced prostate cancer is not related to intake of the gonadotropin-releasing hormone agonist. Nine hundred forty-five patients undergoing radiation therapy were involved.
ACCESSION #
31672206

 

Related Articles

  • Statins linked to decreased risk for prostate tumor inflammation. Haigh, Christen // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p24 

    The article focuses on a study which linked statins to decreased risk for prostate tumor inflammation and may provide a potential mechanism for the prevention and treatment of prostate cancer, presented at the American Urological Association Annual Meeting in Chicago, Illinois on April 25-30, 2009.

  • Statins linked to decreased risk for biochemical recurrence in prostate cancer. Haigh, Christen // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p24 

    The article focuses on a study which associated of statin use with a decreased risk for biochemical recurrence in men who underwent radical prostatectomy, presented at the American Urological Association Annual Meeting in Chicago, Illinois on April 25-30, 2009.

  • An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Klotz, L; Drachenberg, D; Singal, R; Aprikian, A; Fradet, Y; Kebabdjian, M; Zarenda, M; Chin, J // Prostate Cancer & Prostatic Diseases;Dec2014, Vol. 17 Issue 4, p320 

    Background:Bicalutamide is a widely used, relatively non-toxic anti-androgen, particularly when used in combination with androgen deprivation. In men on combined androgen blockade (CAB), the typical dose is 50 mg per day. For men receiving monotherapy with bicalutamide anti-androgen, the dose is...

  • Introduction. Brawer, Dr M K // Prostate Cancer & Prostatic Diseases;1999 Supplement 1, Vol. 2 Issue 1, p1 

    Highlights the 8th International Prostate Cancer Update which was held in Beaver Creek, Colorado from January 28 to February 1, 1998. Activities of the event; Significance of the event.

  • Treatment of Prostate Cancer with Goserelin and Radiotherapy. Schoen, Sheldon S. // New England Journal of Medicine;12/04/97, Vol. 337 Issue 23, p1693 

    A letter to the editor is presented in response to an article by Boll et al. about using Goserelin and Radiotherapy to treat prostate cancer, which appeared in the July 31, 1997 issue of the magazine.

  • Treatment of Prostate Cancer with Goserelin and Radiotherapy. Vicini, Frank A.; Kini, Vijay R.; Martinez, Alvaro A. // New England Journal of Medicine;12/04/97, Vol. 337 Issue 23, p1693 

    A letter to the editor is presented in response to an article by Bolla et al. in the July 31, 1997 issue, which pertains to the treatment of prostate cancer with Goserelin and radiotherapy.

  • Treatment of Prostate Cancer with Goserelin and Radiotherapy. Bolla, Michel; Collette, Laurence // New England Journal of Medicine;12/04/97, Vol. 337 Issue 23, p1693 

    A response by Bolla et al. to letters to the editor about their article about treating prostate cancer with Goserelin and Radiotherapy, which appeared in the July 31, 1997 issue of the magazine, is presented.

  • BAUS Section of Oncology and The British Prostate Group Joint Meeting.  // Prostate Cancer & Prostatic Diseases;2001, Vol. 4 Issue 1, p8 

    Presents abstracts of studies presented at the BAUS Section of Oncology and the British Prostate Group Joint Meeting held in November 15 through 17, 2000 in Newport, Wales. 'Prostate Epithelial Stem Cells Can Be Isolated on the Basis of a[sub2]�[sub1] Integrin Expression,' by A.T. Collins...

  • Urological Calendar.  // Urology Journal;Winter2012, Vol. 9 Issue 1, p443 

    A calendar of worldwide events related to urology in 2012 is presented which includes the 2nd World Symposium on Active Surveillance on Prostate Cancer, the 59th Annual Kimbrough Seminar, and the Annual Scientific Conference of the Canadian Society of Transplantation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics